{"entity":{"id":"nct06921837","kind":"trial","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","aka":[],"tldr":"A phase 1/2 trial of BDC-4182 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Bolt Biotherapeutics, Inc., now recruiting.","summary":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer is a phase 1/2 interventional study registered as NCT06921837 by Bolt Biotherapeutics, Inc., with 122 participants planned, started 2025-05-26 and due to reach its primary completion in 2027-05. Interventions recorded: BDC-4182.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06921837","url":"https://clinicaltrials.gov/study/NCT06921837"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["bdc-4182"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06921837","phase":"1/2","setting":"A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer","sponsor":"Bolt Biotherapeutics, Inc.","enrolled":122,"outcomes":[]},"route":"/trials/nct06921837/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"bdc-4182","kind":"drug","name":"BDC-4182","route":"/drugs/bdc-4182/"}]}}